

Veena Shankaran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1502740/publications.pdf>

Version: 2024-02-01

46
papers

1,864
citations

394421

19
h-index

265206

42
g-index

48
all docs

48
docs citations

48
times ranked

2698
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparities in post-operative surveillance testing for metastatic recurrence among colorectal cancer survivors. <i>Journal of Cancer Survivorship</i> , 2022, 16, 638-649.	2.9	4
2	S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 372-380.	6.3	28
3	Risk of Adverse Financial Events in Patients With Cancer: Evidence From a Novel Linkage Between Cancer Registry and Credit Records. <i>Journal of Clinical Oncology</i> , 2022, 40, 884-891.	1.6	18
4	Financial Navigation in Cancer Care Delivery: State of the Evidence, Opportunities for Research, and Future Directions. <i>Journal of Clinical Oncology</i> , 2022, 40, 2291-2294.	1.6	21
5	Real-world practice patterns in the diagnosis of recurrent metastatic breast cancer in Washington state.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13640-e13640.	1.6	0
6	A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas. <i>Advances in Therapy</i> , 2021, 38, 707-720.	2.9	5
7	Inequitable access to surveillance colonoscopy among Medicare beneficiaries with surgically resected colorectal cancer. <i>Cancer</i> , 2021, 127, 412-421.	4.1	5
8	Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. <i>JCO Oncology Practice</i> , 2021, 17, e1728-e1737.	2.9	7
9	Healthcare utilization and costs in hepatocellular carcinoma (HCC) patients treated at a large referral center in Washington (WA) State.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16149-e16149.	1.6	0
10	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
11	Couple Communication in Cancer: Protocol for a Multi-Method Examination. <i>Frontiers in Psychology</i> , 2021, 12, 769407.	2.1	9
12	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
13	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020, 16, 525-525.	2.9	1
14	Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. <i>JCO Oncology Practice</i> , 2020, 16, e1543-e1552.	2.9	6
15	Comparison of Treatment, Cost, and Survival in Patients With Metastatic Colorectal Cancer in Western Washington, United States, and British Columbia, Canada. <i>JCO Oncology Practice</i> , 2020, 16, e425-e432.	2.9	5
16	Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. <i>Contemporary Clinical Trials</i> , 2020, 95, 106037.	1.8	4
17	Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma. <i>Advances in Therapy</i> , 2020, 37, 3392-3403.	2.9	11
18	Economic Impact of Imaging Overutilization in Cancer Care. <i>Journal of the American College of Radiology</i> , 2020, 17, 137-140.	1.8	2

#	ARTICLE	IF	CITATIONS
19	A theoretical model of financial burden after cancer diagnosis. <i>Future Oncology</i> , 2020, 16, 3095-3105.	2.4	22
20	A Pilot Study of a Comprehensive Financial Navigation Program in Patients With Cancer and Caregivers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1366-1373.	4.9	47
21	Financial hardship in metastatic colorectal cancer patients. <i>Colorectal Cancer</i> , 2020, 9, .	0.8	0
22	Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. <i>Oncologist</i> , 2019, 24, 1039-e642.	3.7	16
23	Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 171-178.	2.3	20
24	A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i> -Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i> -Amplified Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2414-2423.	7.0	54
25	Pilot Feasibility Study of an Oncology Financial Navigation Program. <i>Journal of Oncology Practice</i> , 2018, 14, e122-e129.	2.5	149
26	Financial Burden of Cancer Care. , 2018, , 61-61.		0
27	Links Between Communication and Relationship Satisfaction Among Patients With Cancer and Their Spouses: Results of a Fourteen-Day Smartphone-Based Ecological Momentary Assessment Study. <i>Frontiers in Psychology</i> , 2018, 9, 1843.	2.1	36
28	Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care. <i>Seminars in Hematology</i> , 2018, 55, 185-188.	3.4	27
29	Insurance Coverage and Aid-in-Dying Medication Costs—Reply. <i>JAMA Oncology</i> , 2017, 3, 1138.	7.1	3
30	An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 686.	7.1	94
31	Drug Price Inflation and the Cost of Assisted Death for Terminally Ill Patients—Death With Indignity. <i>JAMA Oncology</i> , 2017, 3, 15.	7.1	9
32	The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 407-411.	0.9	34
33	Development of a financial literacy course for patients with newly diagnosed cancer. <i>American Journal of Managed Care</i> , 2017, 23, S58-S64.	1.1	10
34	Positron emission tomography for initial staging of esophageal cancer among medicare beneficiaries. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 395-402.	1.4	1
35	Improving Price Transparency in Cancer Care. <i>Journal of Oncology Practice</i> , 2016, 12, 44-47.	2.5	29
36	The Economics of Personalized Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 123-129.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 980-986.	1.6	642
38	Addressing the Financial Burden of Cancer Treatment. <i>JAMA Oncology</i> , 2015, 1, 273.	7.1	49
39	Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 41.	3.0	8
40	Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4001-4001.	1.6	28
41	Utilization of patient assistance programs for oral chemotherapy at a comprehensive cancer center.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17530-e17530.	1.6	0
42	Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer. <i>Oncologist</i> , 2014, 19, 892-899.	3.7	19
43	Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2013, 12, 204-213.e1.	2.3	15
44	Risk Factors for Financial Hardship in Patients Receiving Adjuvant Chemotherapy for Colon Cancer: A Population-Based Exploratory Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1608-1614.	1.6	246
45	Managing the Financial Impact of Cancer Treatment: The Role of Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1037-1042.	4.9	10
46	Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions. <i>Oncologist</i> , 2010, 15, 157-167.	3.7	28